WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

SHANGHAI and AUSTIN, Texas, April 8, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.


In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the United States, China and other territories. In addition, he will play a key role in forging and maintaining strong connections between our customers and WuXi's business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.


Dr. Hausheer brings more than 30 years' experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.


"We're very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer," said Mr. Edward Hu, Co-CEO of WuXi AppTec. "Dr. Hausheer's rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi's clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world."


Prior to joining WuXi, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.


Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents.


About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com


Cision View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-appoints-dr-frederick-h-hausheer-as-chief-medical-officer-300825787.html

Related Links :

http://www.wuxiapptec.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【網民職場Talk】下屬奉旨幫上司執手尾?打工仔列慘痛經歷

    打工仔工作繁忙,加上工時長,每天與同事相處的時間比家人、伴侶、朋友還要多,如果不幸遇上能力不高的上司,更會為工作添煩添亂。一個體貼下屬、表現出眾的上司,可謂可遇不可求,當你在職場打滾多年後,或許會發現職位高低往往與能力的高低不成正比。有網民向社交媒體專頁《奴工處》投稿,分享為人下屬的辛酸。

  • 【人才管理】經濟環境轉差取消聚餐 分析企業4個節流方法

    【晴報專訊】本港經濟環境轉差,有網民表示最近知悉公司為節流而取消冬至聚餐,感到無奈。另有網民認為與其舉辦聚餐,不如讓員工放半日假。有人力顧問表示,中小企的管理方式較彈性,部分公司會因應市況而取消聚餐,寧願預留資金應付新年後更嚴峻的經濟環境。

  • 【職場熱話】美企大派聖誕花紅 198名員工分7800萬!

    又到聖誕,又到聖誕……不少打工仔都期待放假輕鬆一下,度過開心聖誕。日前美國馬里蘭州一間房地產公司就大派花紅,將接近8,000萬港元的年終花紅,發放給198名員工,當作他們的聖誕禮物,有不少員工在拿到花紅時更當場落淚。

  • 【政府工略】政府合約僱員將與公務員睇齊 同享17日年假

    【晴報專訊】政府非公務員合約僱員有薪公眾假期,將與公務員看齊。港府向立法會提交文件,透露明年4月1日將予所有合約僱員「加假」5天,各人可享有17天有薪公眾假期。

  • 【職場文化】樂高辦公室斥700萬大變身 茶水間變「蘭桂坊」

    【經濟日報專訊】樂高(LEGO)進駐香港22年,深受大小朋友歡迎。樂高香港辦公室斥資700萬元進行大變身,採用北歐簡約風格設計,同時注入濃厚的香港街道及交通文化特色,打造「小香港」。樂高邀請本港模型家洪子健,以積木拼砌多件辦公室裝飾,當中包括首枝3D自動轉換訊號的紅綠燈。

  • 【企業管理】Burger King 錯誤優惠致蝕錢? 只因一種漢堡

    【經濟日報專訊】Burger King 在美國以經常推出折扣優惠作招徠,但近日該公司最大的加盟商 Carrols Restaurant Group 便因為於 6 月 3 日至 8 月 26 日期間,提供錯誤的優惠,招致約 830 萬美元(約 6,500 萬港元)損失。

  • 【職場人際】上司與下屬如癡男怨女?發生衝突應咁樣做

    【經濟日報專訊】職場上容易產生衝突和糾紛,本地也曾發生不少職場衝突事件,若沒有適當處理,鬧上法庭不免需時又花錢。專家建議,勞資雙方遇到衝突時,考慮以調解形式介入,協助雙方進行適當溝通,尋求解決辦法。

  • 【職場小學問】5個簡單方法 令會議更有效率

    不少辦公室都有著會議文化,每星期開會數次,向上司/老闆匯報工作進度,或與同事Brainstorm刺激思維。然而,員工逗留在會議室的時間愈長,用於銷售、創作和生產的時間就愈少,因此過份冗長或過多的會議,不但影響工作進度,更會打擊士氣。如果你想會議更有效率,可參考以下5個簡單的方法:

  • 【人才管理】新人難教又怕醜 4招有助快速成長

    主管常埋怨新人辦事能力低,沒法承受壓力,而新人則埋怨主管無好好教導,或是怕犯錯給同事添麻煩。雙方不了解對方,成為了惡性循環。作為主管,經驗比新人多,應主動出手了解下屬「為什麼會這樣」。以下就有帶領新人的4個原則,讓主管好好教導新人:

  • 【人才管理】本地公司因應交通 允員工在家工作

    【經濟日報專訊】反修例風波觸發連串示威,有團體計劃周一(9月2日)及周二(9月3日)發起「三罷」,促請政府回應市民訴求。